Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer

Current Opinion in Oncology

Volumn 11, Issue 2, 1999, Pages 116-122

  Rozengurt, Enrique ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CELL RECEPTOR; GROWTH FACTOR; NEUROPEPTIDE;

AUTOCRINE EFFECT; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MITOGENESIS; MOLECULAR BIOLOGY; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

AUTOCRINE COMMUNICATION; CELL CYCLE; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION;

EID: 0032995692     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199903000-00007     Document Type: Review

References (88)

1. Gether U, Kobilka BK: G Protein-coupled receptors II mechanisms of agonist activation. J Biol Chem 1998, 273:17979-17982.
2. Ji TH, Grossmann M, Ji I: G protein-coupled receptors I. Diversity of receptor-ligand interactions. J Biol Chem 1998, 273:17299-17302.
3. Reubi JC, Schaer JC, Waser B: Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997, 1386.
4. Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, Raue F, Becker W: Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998, 25:424-430.
5. Schreiber G, Campa MJ Prabhakar S, O'Briant K, Bepler G, Patz EF, Jr: Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res 1998, 18:1787-1792.
6. North WG, Fay MJ Longo KA, Du J: Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide Cancer Res 1998, 58:1866-1871. Expression of V1a, V1b, and of an abnormal form of V2 is demonstrated. This paper further substantiates a role of vasopressin in SCLC.
7. Lotan R: Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev 1997, 16:349-356.
8. Ravi RK, Scott FM, Cuttitta F, Weber E, Kalemkerian GP, Nelkin BD, Madry M: Induction of gastrin releasing peptide by all-trans retinoic acid in small cell lung cancer cells. Oncol Rep 1998, 5:497-501.
9. de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M: Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res 1997, 9:89-98.
10. Beottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM: Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997, 57:5564-5570. Transgenic mice overexpressing a dominant-negative mutant form of the type II TGF-β receptor were generated and their response to carcinogen challenge was examined. An early increase in the incidence of lung tumors was observed in addition to increased incidence and multiplicity of mammary tumors.
11. De M, Yan W, de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M: Functional characterization of transforming growth factor beta type II receptor mutants in human cancer. Cancer Res 1998, 58:1986-1992.
12. Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, et al.: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998, 4:241-249.
13. Krystal GW, Hines SJ, Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56:370-376.
14. Pietsch T, Nicotra MR, Fraioli R, Wolf HK, Mottolese M, Natali PG: Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 1998, 75:171-175.
15. Willett CG, Wang MH, Emanuel RL, Graham SA, Smith Dl, Shridar V, et al.: Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol 1998, 18:489-496.
16. Kawai T, Hiroi S, Torikata C: Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997, 77:431-436. Platelet-dervied growth factor reactivity (immunostaining and mRNA) was found in a significant proportion of NSCLC cases, suggesting paracrine communication with the surrounding stroma.
17. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM: The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997, 62:554-562.
18. Folkman J: Antiangiogenic gene therapy. Proc Natl Acad Sci U S A 1998, 95:9064-9066.
19. Fontanini G, Vignati S, Boldrini L, Chine S, Lucchi M, Mussi A, et at al.: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861-865
20. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, et al.: Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998, 102:465-472. This report indicates that ENA-78 is an important angiogenic factor for NSCLC. Antibodies against this chemokine prevent tumor growth in vivo.
21. Seufferlein T, Withers DJ, Rozengurt E: Reduced requirement of mitogen-activated protein kinase (MAPK) activity for entry into the S phase of the cell cycle in Swiss 3T3 fibroblasts stimulated by bombesin and insulin. J Biol Chem 1996, 271:21471-21477.
22. Withers DJ, Seufferlein T, Mann D, Garcia B, Jones N, Rozengurt E: Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells. J Biol Chem 1997, 272:2509-2514.
23. Mann DJ, Higgins T, Jones NC, Rozengurt E: Differential control of cyclins D1 and D3 and the cdk inhibitor p27Kip1 by diverse signalling pathways in Swiss 3T3 cells. Oncogene 1997, 14:1759-1766.
24. Seufferlein T. Rozengurt E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996, 56:3895-3897.
25. Seufferlein T, Rozengurt E: Galanin neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 1996, 56:5758-5764.
26. Seckl MJ, Higgins T, Widmer F, Rozengurt E: [D-Arg1,D-Trp5,7,9,Leu 11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997, 57:51-54.
27. Cattaneo MG, D'Atri F, Vicentini LM: Mechanisms of mitogen-activated protein kinase activation by nicotine in small-cell lung carcinoma cells. Biochem J 1997, 328:499-503.
28. Heusch WL, Maneckjee R, Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 1998, 19:551-556.
29. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998, 101:153-159. Expression of c-Raf induces chronic stimulation of the ERK pathway in SCLC and leads to reduced proliferation. These findings indicate that strong Raf kinase signaling is incompatible with SCLC proliferation.
30. Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, et al.: The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J 1998, 330:1451-1460.
31. Sewing A, Wiseman B, Lloyd AC, Land H: High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997, 17:5588-5597.
32. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M: Rafinduced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 Mol Cell Biol 1997, 17:5598-5611.
33. Beekman A, Helfrich B, Bunn PA Jr, Heasley LE: Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth, Cancer Res 1998, 58:910-913. Expression of truncated PLC-β-inhibited signal transduction and colony formation providing further support for the importance of autocrine loops in SCLC growth.
34. Rozengurt E: Gastrointestinal peptide signaling through tyrosine phosphorylation of focal adhesion proteins. Am J Physiol 1998, 275:G177-G182. This article reviews the evidence for a pathway involving G12/13 and Rho that leads to the tyrosine phosphorylation of focal adhesion proteins in the action of neuropeptides.
35. Casamassima A, Rozengurt E: Tyrosine phosphorylation of p130(cas) by bombesin, lysophosphatidic acid, phorbol esters, and platelet-derived growth factor. Signaling pathways and formation of ap130(cas)-Crk complex. J Biol Chem 1997, 272:9363-9370.
36. Tokman MG, Porter RA, Williams CL: Regulation of cadherin-mediated adhesion by the small GTP-binding protein Rho in small cell lung carcinoma cells. Cancer Res 1997, 57:1785-1793.
37. Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M, Sher E, Spano PF: Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci U S A 1998, 95:5366-5371. Chronic treatment of SCLC cell lines with NGF leads to a marked decrease in colony formation and blocked tumorigenicity in nude mice suggesting that NGF reverses SCLC to a less severe phenotype.
38. Bost F, McKay R, Dean N, Mercola D: The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem 1997, 272:33422-33429. The protein kinase JNK may mediate proliferative effects of EGF in NSCLC.
39. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al.: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58:3761-3764.
40. Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, et al.: Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiiflammatory drugs. Anticancer Res 1998, 18:775-782.
41. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 1998, 16:1207-1217.
42. Gouyer V, Gazzaeri S, Bolon I, Drevet C, Brambilla C, Brambilla E: Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998, 18:188-196.
43. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, et al.: Lose of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A 1997, 94:6933-6938.
44. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E: The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998, 58:3926-3931. The results suggest that p19ARF is a novel suppressor of tumor growth.
45. Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE, Matsuda H: Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998, 79:111-115.
46. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T: Correlation between methylation status of the p16/CDKN2 gene and the expression of pl6 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998, 79:215-220.
47. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E: Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 1998, 16:497-504.
48. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, et al.: Role of p27Kip1 and kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 1998, 153:505-513. This reference, along with Yatabe et al. [Cancer Res 1998, 58:1042-1047], indicates that p27Kip1 is markedly reduced in NSCLC.
49. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, et al.: Role of p27Kip1 and kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 1998, 153:505-513. This reference, along with Yatabe et al. [Cancer Res 1998, 58:1042-1047], indicates that p27Kip1 is markedly reduced in NSCLC.
50. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, et al.: p27kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas, Cancer Res 1998, 58:1042-1047. This paper, along with Kawana et al. [Am J Pathol 1998, 153:505-513], indicates that p27Kip1 is markedly reduced in NSCLC.
51. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, et al.: p27kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas, Cancer Res 1998, 58:1042-1047. This paper, along with Kawana et al. [Am J Pathol 1998, 153:505-513], indicates that p27Kip1 is markedly reduced in NSCLC.
52. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, La Rocca R, Merlo G, Chella A, Angeletti CA, Dalla Palma P, Bevilacqua G Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998, 75:167-192.
53. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ: p16ink4a participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 1998, 18:378-387.
54. Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD, Warburton D: Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol 1997, 273:L941-L949.
55. Agarwal ML, Taylor WR, Chemov MV, Chemova OB, Stark GR: The p53 network. J Biol Chem 1998, 273:1-4. This paper presents a good and succinct review of p53 signaling.
56. Jost CA, Marin MC, Kaelin WG Jr: p73 is a human p53-related protein that can induce apoptosis. Nature 1997, 389:191-194.
57. Mai M, Yokomizo A, Oian C, Yang P, Tindall DJ, Smith DI, Liu W: Activation of p73 silent allele in lung cancer. Cancer Res 1998, 58:2347-2349.
58. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T: Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998, 58:1380-1383.
59. Buckbinder L, Velasco-Miguel S, Chen Y, Xu N, Talbott R, Gelbert L, et al.: The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A 1997, 94:7868-7872. A novel target for p53 is identified which may regulate cellular sensitivity to GPCR signaling.
60. Virmani AK, Fong KM, Kodagoda D, Mclntire D, Hung J, Tonk V, et al.: Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998, 21:308-319.
61. Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker CE Jr, Hahner L, et al.: Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res 1997, 57:1344-1352.
62. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, et al.: FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer related FHIT cDNA splicing aberrations. Cancer Res 1997, 57:2256-2267.
63. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT: Chromosome 3p14 alterations in lung cancer: evidence that FHIT axon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998, 58:1804-1807.
64. Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei M, et al.: Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998, 16:3151-3157.
65. Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosier A, et al.: Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci U S A 1998, 95:5484-5489. The His96/Asn mutant of Fhit reduces the rate of ApppA hydrolase activity but does not interfere with its tumor suppressing activity. In this paper, the structure of Fhit with substrate bound is reported.
66. Pekarsky Y, Campiglio M, Siprashvili Z, Druck T, Sedkov Y, Tillib S, et al.: Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc Natl Acad Sci U S A 1998, 95:8744-8749.
67. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, at al.: PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998, 17:475-479.
68. Kohno T, Takahashi M, Manda R, Yokota J: Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998, 22:152-156.
69. Kim SK, Su LK, Oh Y, Kemp BL, Hong WK, Mao L: Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene 1998, 16:89-93.
70. Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, et al.: Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci U S A 1998, 95:8153-8158. In this article, tumor suppressor activity is demonstrated by a functional assay.
71. Takei K, Kohno T, Hamada K, Takita J, Noguchi M, Matsuno Y, et al.: A novel tumor suppressor locus on chromosome 18q involved in the development of human lung cancer. Cancer Res 1998, 58:3700-3705.
72. Suzuki K, Ogura T, Yokose T, Nagai K, Mukai K, Kodama T, et al.: Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer 1998, 79:384-389.
73. Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschleager M: Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 1997, 272:29301-29308.
74. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al.: p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998, 18:213-217. This article, along with those by Esposito et al. [Cancer Res 1997, 57:3381-3385] and Bennett et al. [Clin Cancer Res 1998, 4:1499-1506]. provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
75. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al.: p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998, 18:213-217. This article, along with those by Esposito et al. [Cancer Res 1997, 57:3381-3385] and Bennett et al. [Clin Cancer Res 1998, 4:1499-1506]. provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
76. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al.: p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998, 18:213-217. This article, along with those by Esposito et al. [Cancer Res 1997, 57:3381-3385] and Bennett et al. [Clin Cancer Res 1998, 4:1499-1506]. provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
77. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al.: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385. This article, along with those by Caputi et al. [Am J Respir Cell Mol Biol 1998, 18:213-217] and Bennett et al. [Clin Cancer Res 1998, 4:1499-1506], provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
78. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al.: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385. This article, along with those by Caputi et al. [Am J Respir Cell Mol Biol 1998, 18:213-217] and Bennett et al. [Clin Cancer Res 1998, 4:1499-1506], provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
79. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al.: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385. This article, along with those by Caputi et al. [Am J Respir Cell Mol Biol 1998, 18:213-217] and Bennett et al. [Clin Cancer Res 1998, 4:1499-1506], provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
80. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, et al.: p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 1998, 4:1499-1506. This article, along with those by Caputi et al. [Am J Respir Cell Mol Biol 1998, 18:213-217] and Esposito et al. [Cancer Res 1997, 57:3381-3385], provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
81. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, et al.: p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res l998, 4:1499-1506. This article, along with those by Caputi et al. [Am J Respir Cell Mol Biol 1998, 18:213-217] and Esposito et al. [Cancer Res 1997, 57:3381-3385], provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
82. tBennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, et al.: p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res l998, 4:1499-1506. This article, along with those by Caputi et al. [Am J Respir Cell Mol Biol 1998, 18:213-217] and Esposito et al. [Cancer Res 1997, 57:3381-3385], provides examples in which molecular markers could be used to refine the prognosis of NSCLC.
83. Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, et al.: Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998, 58:2533-2536.
84. Roth JA: Gene replacement strategies for lung cancer. Curr Opin Oncol 1998, 10:127-132.
85. Seckl MJ, Rozengurt E: Substance P analogues act a broad-spectrum neuropeptide antagonists. Lett Pept Sci 1998, 5:199-204. This review summarizes studies indicating that substance P antagonists block the binding and biological effects of multiple neuropeptides linked to the activation of Gq.
86. Seckl MJ, Higgins T, Rozengurt E: [D-Arg1,D-Trp5,7,9,Leu 11]Substance P coordinately and reversibly inhibits bombesin- and vasopressin-induced signal transduction pathways in Swiss 3T3 cells. J Biol Chem 1996, 271:29453-29460.
87. Krystal GW, Carlson P, Litz J: Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res 1997, 57:2203-2208.
88. Parrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D: Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997, 138:1427-1433.